Foretinib GSK1363089

Size	Price	Stock	Quantity
Get Quotation Now Add to Cart Bulk Inquiry

Shipping and handling fee USD40, Free delivery is qualified when the total value of your order exceeds USD500.If the item is temporarily out of stock. Please email to order@pharm-intermediates.com,we will inform you when we have it in stock.

Chemical Information

Product name：Foretinib GSK1363089	Purity：98% min
CAS NO：849217-64-7	Solubility：DMSO : ≥ 38 mg/mL (60.06 mM)
Molecular Formula：C₃₄H₃₄F₂N₄O₆	Package：Package according to customer requirements
Molecular Weight：632.654	Storage：Store at -20℃

Quality control

COA

Remarks

Foretinib, also known as XL880 and GSK1363089, is an orally bioavailable small molecule with potential antineoplastic activity. MET/VEGFR2 inhibitor GSK1363089 binds to and selectively inhibits hepatocyte growth factor (HGF) receptor c-MET and vascular endothelial growth factor receptor 2 (VEGFR2), which may result in the inhibition of tumor angiogenesis, tumor cell proliferation and metastasis. The proto-oncogene c-MET has been found to be over-expressed in a variety of cancers.

Properties:

Density: 1.372g/cm3

Boiling Point: 828.475ºC at 760 mmHg

Flash Point: 454.846ºC

Refractive Index: 1.649

Related Prodcuts:

LY2874455; ZM-306416; ZM323881; Tyrphostin A9; Orantinib; Brivanib; SU5402; Semaxanib; SAR131675; Lucitanib; Apatinib; SKLB610; Altiratinib; SGI-7079; AZD2932

References

[1]. Qian F, et al. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases. Cancer Res, 2009, 69(20), 8009-8016.

[2]. Kataoka Y, et al. Foretinib (GSK1363089), a multi-kinase inhibitor of MET and VEGFRs, inhibits growth of gastric cancer cell lines by blocking inter-receptor tyrosine kinase networks. Invest New Drugs, 2011.